SUMMARY

Heart failure management is determined by left ventricular ejection fraction, distinguishing between preserved and reduced ejection fraction phenotypes.

The 4 pillars of guideline-directed medical therapy for heart failure with reduced ejection fraction (HFrEF) are renin–angiotensin–aldosterone system inhibitors, beta blockers, mineralocorticoid receptor antagonists and sodium-glucose co-transporter 2 (SGLT2) inhibitors.

Pharmacological treatment of heart failure with preserved ejection fraction (HFpEF) centres on SGLT2 inhibitors and mineralocorticoid receptor antagonists, with additional therapies guided by the patient’s symptoms and comorbidities.

Early optimisation of guideline-directed medical therapy reduces mortality and heart failure hospitalisations. Structured multidisciplinary follow-up is essential to achieve optimal patient outcomes.

 

Introduction

Heart failure (HF) is a clinical syndrome with typical symptoms and signs, including dyspnoea and fatigue, that generally occur on exertion but can also occur at rest, particularly when recumbent. These symptoms arise from abnormalities in cardiac structure or function that impair ventricular filling or ejection.1

Investigations for underlying causes of HF should be undertaken at diagnosis, and these conditions should be managed alongside HF-specific pharmacotherapy.1 Some causes of HF, such as cardiac amyloidosis and hypertrophic cardiomyopathy, require treatment that differs from the standard approach.

The prevalence of HF in Australia is growing, affecting at least 2% of adults, and it remains a leading cause of hospitalisation.2 Pharmacological therapy has substantially improved outcomes, and chronic ambulatory HF now has an estimated 1-year survival rate of 87% and a 5-year survival rate of 60%.3

Guideline-directed medical therapy (GDMT), also known as foundational medical therapy, involves multiple classes of drugs that target neurohormonal pathways that contribute to disease progression. Classification of HF by left ventricular ejection fraction (LVEF) guides the treatment algorithm. The most important shift in treatment has been from the sequential introduction of medications to the early initiation of all 4 pillars of disease-modifying therapy in HF with reduced ejection fraction (HFrEF). GDMT should be optimised wherever possible, and treatment should be individualised, particularly in older adults and those with frailty or multimorbidity, where a more tailored approach may be required to minimise harm. Additional drug therapies may be added as indicated. GDMT for HF with preserved ejection fraction (HFpEF) is more limited.

This article reviews contemporary pharmacological management of HF in Australian clinical practice.

 

Classification of heart failure

Australian guidelines classify HFrEF as LVEF less than 50% and HFpEF as LVEF 50% or greater.1

The 2026 European Society of Cardiology (ESC) guidelines have adopted a similar classification,4 with HFpEF additionally requiring objective evidence of cardiac structural or functional abnormalities consistent with elevated filling pressures. Importantly, the ESC guidelines have removed HF with mildly reduced ejection fraction (HFmrEF) as a separate phenotype, recognising that a single LVEF threshold is an imperfect discriminator and that LVEF should be interpreted in the clinical context.

One further category is HF with improved ejection fraction (HFimpEF), in which a previously reduced LVEF has increased or normalised. HFimpEF reflects improvement in EF but not resolution of the underlying cardiomyopathy. In most cases, HFimpEF is treated the same as HFrEF, requiring lifelong continuation of GDMT because treatment withdrawal can precipitate relapse.5

 

HFrEF: the 4 pillars

GDMT for patients with HFrEF are known as ‘the 4 pillars’ (Table 1). These are:

  •    renin–angiotensin–aldosterone system inhibitors (angiotensin receptor–neprilysin inhibitor [ARNI], angiotensin converting enzyme inhibitor [ACEi] or angiotensin receptor blocker [ARB])
  •    HF-specific beta blockers
  •    mineralocorticoid receptor antagonists (MRAs)
  •    sodium-glucose co-transporter 2 (SGLT2) inhibitors.Table 1 The 4 pillars used in HFrEF
Drug class Mechanism of action Adverse effects Drug Starting dose Target dose Titration Key monitoring
RAAS inhibitors

ARNI

Causes vasodilation

Reduces sympathetic activity

Enhances diuresis

Angioedema

Hypotension

Sacubitril with valsartan

24 mg sacubitril with 26 mg valsartan twice daily

97 mg sacubitril with 103 mg valsartan twice daily

Double dose every 2 to 4 weeks

Blood pressure: do not increase dose if there is symptomatic hypotension. If there is asymptomatic hypotension, continue dose and repeat blood pressure measurement within 1 week

Bloods: check renal function and potassium within 2 weeks of a dose change and every 6 to 12 months when dose is stable

If eGFR declines by more than 30%, assess volume status, review other contributors (e.g. diuretics, NSAIDs) and, if no other contributors, reduce dose and repeat in 1 to 2 weeks

If potassium is greater than 5.5 mmol/L, assess volume status, ensure no potassium supplementation and, if not successful, reduce dose or stop MRA and/or RAAS inhibitor

ACEi

Reduce vasoconstriction, sodium reabsorption and aldosterone secretion

Hypotension

Worsening renal function

Hyperkalaemia

Chronic cough

Angioedema

Ramipril

1.25 to 2.5 mg daily

10 mg daily

Increase dose every 1 to 2 weeks

Perindopril erbumine

2 mg daily

8 mg daily

Increase dose every 1 to 2 weeks

Perindopril arginine

2.5 mg daily

10 mg daily

Increase dose every 1 to 2 weeks

ARBs

If ACEi intolerant

Reduce vasoconstriction, sodium reabsorption and aldosterone secretion

Hypotension

Worsening renal function

Hyperkalaemia

Candesartan [NB1]

4 mg daily

32 mg daily

Double dose every 2 weeks

Valsartan [NB1]

40 mg twice daily

160 mg twice daily

Increase dose every 1 to 2 weeks

Heart failure–specific beta blockers

Beta blockers

Reduce sympathetic activity

Antiarrhythmic effects

Reverse remodelling

Hypotension

Bradycardia

Fatigue

Bronchospasm

Impotence

Worsening heart failure in congested patients

Masking of hypoglycaemia symptoms

Bisoprolol

1.25 mg daily

10 mg daily

Double dose every 2 weeks

Heart rate: continue therapy if asymptomatic bradycardia (heart rate 50 to 60 beats per minute). If symptomatic bradycardia (heart rate below 50 beats per minute), arrange an ECG to document rhythm, review any other rate-lowering drugs and, if not successful, reduce dose of beta blocker

Blood pressure: continue therapy unless symptomatic hypotension not responsive to RAAS inhibitor changes OR evidence of shock

Congestion: do not increase dose if present

Metoprolol succinate

23.75 mg daily

190 mg daily

Double dose every 2 weeks

Carvedilol

3.125 mg twice daily

25 mg twice daily

Double dose every 2 weeks

Nebivolol

1.25 mg daily

10 mg daily

Double dose every 2 weeks

MRAs

MRAs

Weak diuretic effect

Reduce effects of aldosterone

Hyperkalaemia

Worsening renal function

Hypotension

Gynaecomastia (spironolactone)

Spironolactone

25 mg daily

25 to 50 mg daily (25 mg daily is usually sufficient)

Increase dose after 4 weeks if potassium concentration is 5.0 mmol/L or less and renal function is stable (eGFR decline less than 30%)

Blood pressure: only stop if symptomatic hypotension not responsive to changes with ARNI (or ACEi or ARB) and beta blocker

Bloods: check potassium and renal function 3 to 7 days after initiation, then every 4 weeks for 3 months, then every 3 to 6 months

Eplerenone

25 mg daily

50 mg daily (25 mg is usually sufficient)

SGLT2 inhibitors

SGLT2 inhibitors

Osmotic diuresis and natriuresis

Improve cardiac metabolism

Reduce myocardial fibrosis and inflammation

Euglycaemic ketoacidosis

Hypotension

Genitourinary infections

Dapagliflozin

10 mg daily

10 mg daily

No titration

Renal function: can tolerate up to 30% decline in eGFR in the first month of treatment

Volume status

Empagliflozin

10 mg daily

10 mg daily

No titration

ACEi = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker; ARNI = angiotensin receptor–neprilysin inhibitor; ECG = electrocardiogram; eGFR = estimated glomerular filtration rate; HFrEF = heart failure with reduced ejection fraction, MRAs = mineralocorticoid receptor antagonists; NSAIDs = nonsteroidal anti-inflammatory drugs; RAAS = renin–angiotensin–aldosterone system; SGLT2 = sodium-glucose co-transporter 2 NB1: Candesartan and valsartan are the ARBs with the strongest trial outcome evidence in heart failure.

Each drug class targets a different pathophysiological pathway, and the benefits of each class are independent and additive. The combination of all 4 pillars has been associated with an approximate 60% relative reduction in all-cause mortality compared with no therapy in modelling analyses, which translates to an approximate 5.3 additional years of life in an individual aged 70 years old.6

Rather than maximising one drug before starting another, current practice is for all 4 pillars to be initiated early, with sequential introduction and rapid up-titration according to the patient’s clinical status. Simultaneous initiation may be appropriate in select patients, particularly in hospital. Clinical benefits are seen with subtarget doses, and delays in initiation increase the morbidity and mortality of patients with HFrEF.7

Drug classes in HFrEF

Among renin–angiotensin–aldosterone system inhibitors, an ARNI (sacubitril with valsartan) is recommended as first-line therapy in ambulatory patients, having been shown to reduce the composite outcome of cardiovascular death or HF hospitalisation by 20% compared with enalapril,8,9 in addition to the established mortality benefit of ACEi (approximately 20%) over placebo.10 However, in Australia, the subsidised use of an ARNI through the Pharmaceutical Benefits Scheme (PBS) requires prior stabilisation on an ACEi or ARB. Starting an ARB first allows an easier switch to ARNI, whereas an ACEi requires a 36-hour washout after the last ACEi dose because of the increased risk of angioedema. If an ARNI is contraindicated, an ACEi or ARB may be used long term.

HF-specific beta blockers (bisoprolol, metoprolol succinate, carvedilol and nebivolol) reduce mortality and HF hospitalisation by approximately 30 to 35% in patients with HFrEF compared with placebo.11 They should only be initiated or up-titrated when the patient is euvolaemic because beta blockers can precipitate decompensation in patients with congestion.

MRAs (spironolactone and eplerenone) reduce mortality and HF hospitalisation by approximately 30% compared with placebo.12 They can cause hyperkalaemia, so serum electrolytes and renal function must be monitored after initiation and dose titration. MRAs are generally avoided if the estimated glomerular filtration rate (eGFR) is less than 30 mL/min/1.73 m2; however, they can be continued at a reduced dose if the eGFR is 25 to 30 mL/min/1.73 m2. MRAs have traditionally been avoided if potassium concentrations cannot be maintained below 5.5 mmol/L; however, potassium-lowering drugs, including patiromer (PBS-subsidised) and sodium zirconium cyclosilicate, can facilitate continued MRA use in patients with chronic hyperkalaemia and chronic kidney disease.13 Eplerenone (PBS-subsidised) is an alternative to spironolactone if gynaecomastia develops.

In HFrEF, SGLT2 inhibitors (dapagliflozin and empagliflozin) reduce the composite outcome of HF hospitalisations and cardiovascular death by approximately 25%, with the benefit predominantly driven by reductions in HF hospitalisations. They also improve symptoms and quality of life.14,15 SGLT2 inhibitors can be initiated at an eGFR greater than 25 mL/min/1.73 m2 for dapagliflozin and greater than 20 mL/min/1.73 m2 for empagliflozin. A mild transient decline in eGFR (typically 10 to 30%) may occur after initiation and does not require treatment cessation. Despite this initial decline in eGFR, SGLT2 inhibitors are associated with a slower long-term decline in renal function compared with placebo.16 A larger or progressive decline in renal function should prompt assessment for other causes and consideration of whether treatment should be continued. Patients should be advised about the risk of genitourinary infections and to temporarily stop SGLT2 inhibitors during acute illness or fasting because of the risk of euglycaemic ketoacidosis.

Rapid up-titration

All 4 pillars should ideally be initiated within 4 weeks of diagnosis, with titration towards target or maximum tolerated doses over approximately 6 weeks. Starting low doses of all 4 pillars is preferable to using full doses of fewer medications.7 The STRONG-HF trial showed that titration to target doses within 2 to 3 weeks is feasible and safe and reduces the risk of HF readmission or death at 180 days compared with usual care.17 These findings support early, structured post-diagnosis follow-up, with medication up-titration every 1 to 2 weeks (Table 2). This approach should be individualised in older patients and those with frailty, chronic kidney disease or recurrent decompensations. Multidisciplinary HF programs, including nurse- or pharmacist-led titration, improve attainment of target doses, reduce hospitalisations and improve quality of life.18

Table 2 Structured GDMT up-titration plan for patients with HFrEF, based on the STRONG-HF trial17

Time point Actions Monitoring checklist for each visit Safety thresholds for adjustment

Week 1

Initiate all 4 pillars:

  •    ARNI (or ACEi or ARB)
  •    Beta blocker
  •    MRA
  •    SGLT2 inhibitor

HF Symptoms: dyspnoea, orthopnoea, fatigue

HF Signs: weight, oedema, blood pressure, heart rate

Laboratory results: urea, electrolytes (sodium, potassium), creatinine (eGFR)

Treatment Adherence

Adverse effects

Also provide HF education

Do not up-titrate ARNI (or ACEi or ARB) or MRA if any of the following are present:

  •    potassium greater than 5.0 mmol/L
  •    eGFR less than 30 ml/min/1.73m2
  •    systolic blood pressure less than 95 mmHg

Do not up-titrate beta blocker if any of the following are present:

  •    systolic blood pressure less than 95 mmHg
  •    heart rate less than 55 beats per minute
  •    signs of congestion

Week 1 to 2

Increase dose of 1 to 2 drugs and add in remaining pillars if not already initiated

Adjust diuretics

Week 2 to 3

Up-titrate remaining drugs

Adjust diuretics

Week 3 to 4

Reach target or maximum tolerated doses

Week 6

Stabilisation review

Fine-tune doses

Week 12

Maintain maximum tolerated doses

ACEi = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker; ARNI = angiotensin receptor–neprilysin inhibitor; eGFR = estimated glomerular filtration rate; GDMT = guideline-directed medical therapy; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; MRA = mineralocorticoid receptor antagonist; SGLT2 = sodium-glucose co-transporter 2

A consensus Australian approach to initiating the 4 pillars is outlined in Figure 1.8 If congestion is present, an ARNI (or ACEi or ARB) and an SGLT2 inhibitor should be started first, followed by an MRA. Once the patient is euvolaemic, an HF-specific beta blocker should be added. If euvolaemic, an ARNI (or ACEi or ARB) and beta blocker can be started first, followed by an MRA and SGLT2 inhibitor.


Figure 1 Australian consensus approach to up-titration of GDMT in HFrEF8

Flow chart outlining the Australian consensus approach to up-titration of guideline-directed medical therapy (GDMT) in heart failure with reduced ejection fraction. If congestion is present, initiate diuretic therapy until euvolaemia is achieved, then reduce diuretics to the lowest effective dose. Start GDMT with an ARNI (or ACEi or ARB) and an SGLT2 inhibitor, followed by an MRA. Add a heart failure–specific beta blocker once the patient is euvolaemic. If the patient is already euvolaemic, start an ARNI (or ACEi or ARB) and beta blocker first, followed by an MRA and SGLT2 inhibitor. Up-titrate GDMT to the maximum tolerated doses, preferentially increasing the beta blocker dose unless congestion is present or the heart rate is below 50 beats per minute.

For maximum therapeutic benefits, each drug should be titrated to the target dose, ideally within 6 weeks (Table 1). Clinical review should occur 1 to 2 weeks after each dose change. If there is a decline in eGFR of more than 30%, medications and fluid status should be reassessed. Asymptomatic hypotension is acceptable during up-titration, usually if systolic blood pressure remains at least 90 mmHg. However, symptomatic hypotension warrants prompt review. If the patient appears hypovolaemic, consider reducing the diuretic dose, reducing vasodilators and splitting doses of ACEi, ARB or beta blockers before reducing GDMT. In patients with no cardiac device in situ whose heart rate is below 50 beats per minute while taking a beta blocker, the beta blocker dose may need to be reduced.

Older age and frailty are not contraindications to GDMT, but adverse effects such as hypotension, dizziness and falls may occur during up-titration, so treatment should be individualised.19 Treatment should be initiated at low doses and up-titrated slowly. GDMT should not be withheld or underused because mortality and quality of life benefits are maintained in these patients.

 

HFpEF

HFpEF is characterised by diastolic dysfunction, in which the left ventricle is unable to relax adequately during filling. This leads to elevated filling pressures, particularly on exertion, resulting in exertional dyspnoea.20 Older age and female sex are major risk factors, along with cardiometabolic conditions including obesity, diabetes, hypertension, chronic kidney disease, atrial fibrillation and sleep-disordered breathing. Pharmacological treatment of HFpEF is centred on SGLT2 inhibitors and MRAs, with loop diuretics used to manage congestion and additional therapies tailored to the patient and their comorbidities (Table 3).21

Table 3 Drugs used in HFpEF

Drug class Mechanism of action Adverse effects Drug Starting dose Target dose Titration Key monitoring

SGLT2 inhibitors

Osmotic diuresis and natriuresis

Improve cardiac metabolism

Reduce myocardial fibrosis and inflammation

Euglycaemic ketoacidosis

Hypotension

Genitourinary infections

Dapagliflozin

10 mg daily

10 mg daily

No titration

Renal function: can tolerate up to 30% decline in eGFR in the first month of treatment

Volume status

Empagliflozin

10 mg daily

10 mg daily

No titration

Nonsteroidal MRA

Reduces effects of aldosterone

Worsening renal function

Hypotension

Hyperkalaemia (lower risk than spironolactone)

Finerenone

20 mg daily if eGFR 60 mL/min/1.73 m2 or greater

10 mg daily if eGFR 25 to 59 mL/min/1.73 m2

40 mg daily if eGFR 60 mL/min/1.73 m2 or greater

20 mg daily if eGFR 25 to 59 mL/min/1.73 m2

Increase dose after 4 weeks if potassium is 5.0 mmol/L or less and eGFR has not declined by more than 30% from previous measurement

Do not change dose if potassium is greater than 5.0 mmol/L but less than 5.5 mmol/L, or if eGFR declines more than 30%

Halve dose if potassium is greater than 5.5 mmol/L (or withhold if on 10 mg dose) and restart at lower dose once potassium is less than 5.5 mmol/L

Blood pressure: only stop if symptomatic hypotension is not responsive to changes with antihypertensive therapy

Bloods: check potassium and renal function 3 to 7 days after initiation or dose increase, then every 4 weeks for 3 months, then every 3 to 6 months

Volume status

MRA

Weak diuretic

Reduces effects of aldosterone

Hyperkalaemia

Worsening renal function

Hypotension

Gynaecomastia

Spironolactone

25 mg daily

25 to 50 mg daily

Increase dose after 4 weeks if 5.0 mmol/L or less and eGFR has not declined by more than 30%

Blood pressure: only stop if symptomatic hypotension not responsive to changes with ARNI (or ACEi or ARB) and beta blocker

Bloods: check potassium and renal function 3 to 7 days after initiation, then every 4 weeks for 3 months, then every 3 to 6 months

Loop diuretic

Reduces sodium and water retention

Renal dysfunction

Hypokalaemia

Worsened gout

Hypotension

Furosemide

20 to 40 mg once or twice daily

–

Titrate depending on fluid status to a maintenance dose of 20 to 400 mg daily

Weight: aim for 0.5 to 1 kg loss per day if congested and titrate dose based on patient’s dry weight

Blood pressure: assess volume status and reduce or stop if there are no signs or symptoms of congestion

Bloods: renal function, potassium, sodium

ACEi = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker; ARNI = angiotensin receptor–neprilysin inhibitor; eGFR = estimated glomerular filtration rate; HFpEF = heart failure with preserved ejection fraction; MRA = mineralocorticoid receptor antagonist; SGLT2 = sodium-glucose co-transporter 2

SGLT2 inhibitors should be initiated in all patients with HFpEF unless contraindicated. SGLT2 inhibitors reduce the composite outcome of cardiovascular death and HF hospitalisation by 20% compared with placebo, primarily through a reduction in HF hospitalisations.14

MRAs reduce the composite outcome of cardiovascular mortality and worsening HF in patients with HFpEF. Finerenone, a nonsteroidal MRA, reduced the composite outcome of total worsening HF events (first or recurrent hospitalisation and urgent visit for HF) and cardiovascular death by 16% compared with placebo in patients with HF with LVEF 40% or greater.22 This benefit was predominantly driven by a reduction in worsening HF events, with no significant reduction in cardiovascular mortality. Serum potassium and renal function should be monitored because of the risk of hyperkalaemia (Table 3). Because finerenone is nonsteroidal, it has a lower incidence of gynaecomastia than spironolactone. Finerenone should not be combined with other MRAs, including spironolactone or eplerenone, because of the risk of hyperkalaemia. Spironolactone may be considered in patients with HFpEF to reduce the risk of HF hospitalisation, although it did not significantly reduce the primary composite outcome in the TOPCAT trial.23

In HFpEF, ARNI, ACEi and ARBs have not demonstrated the consistent outcome benefits seen with SGLT2 inhibitors and MRAs,24-26 therefore, they are not recommended for routine use in HFpEF. However, they may have a role in select patients, particularly for the treatment of hypertension.

Beta blockers should be avoided in HFpEF unless there is comorbid angina or atrial fibrillation requiring rate control.21

 

Additional drug therapies in HFrEF and HFpEF

Diuretics

Patients with clinical congestion should receive diuretics to improve symptoms and achieve euvolaemia, regardless of ejection fraction.27 Loop diuretics, such as furosemide, are first-line therapy and should be titrated to effect. In the event of diuretic resistance, a thiazide or thiazide-like diuretic (e.g. hydrochlorothiazide, metolazone) may be added, a strategy known as sequential nephron blockade. This approach should be initiated in hospital or a closely monitored community setting because of the risk of rapid volume depletion, electrolyte disturbance and renal impairment. Once euvolaemia is achieved, diuretics should be reduced to the lowest effective dose to prioritise GDMT. Some patients require ongoing diuretic therapy to maintain euvolaemia.

Intravenous iron

Intravenous iron has shown benefits in reducing HF hospitalisations and symptoms and increasing exercise capacity in patients with iron deficiency.28 Intravenous iron infusion should be given to iron-deficient patients with symptomatic HFrEF,, with or without anaemia, if ferritin concentrations are less than 100 micrograms/L or if transferrin saturations are below 20% and ferritin concentrations are 100 to 299 micrograms/L. Both ferric carboxymaltose and ferric derisomaltose are PBS-subsidised. Currently there is no established role for intravenous iron in HFpEF.

Oral iron has not been shown to improve symptoms or exercise capacity, and is generally ineffective at replenishing iron stores, in people with HFrEF.29

Incretin-based therapies

Incretin-based therapies, such as glucagon-like peptide-1 (GLP-1) receptor agonists and dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists, are emerging as a treatment for obesity-related HFpEF. Obesity contributes to HFpEF through increased blood volume, elevated cardiac filling pressures, metabolic stress and systemic inflammation, which promote myocardial fibrosis and stiffness.30

Semaglutide, a GLP-1 receptor agonist, has been shown to improve weight, exercise capacity and quality of life.31 Tirzepatide, a dual GIP/GLP-1 receptor agonist, reduced the composite outcome of cardiovascular death and worsening HF events.32 The role of incretin-based therapies in HFpEF without obesity, and their effects on mortality, are uncertain.

In HFrEF, incretin-based therapies should be used with caution because they may increase heart rate and the risk of decompensation.33

Incretin-based therapies are not currently approved by the Australian Therapeutic Goods Administration for HF, and trials are ongoing to clarify their role in HF management.

 

Additional drug therapies for persistent symptoms despite GDMT in HFrEF

Vericiguat

Vericiguat is an oral drug that enhances the nitric oxide–cGMP pathway, which is impaired in HF. In patients with HFrEF and recent decompensation, vericiguat reduced the composite outcome of cardiovascular death and HF hospitalisation by 10% compared with placebo.34 Vericiguat is PBS-subsidised for patients stabilised following a recent HF decompensation requiring hospitalisation or intravenous diuretic therapy who are receiving GDMT.

Ivabradine

Ivabradine reduces heart rate and is used in patients with HFrEF who remain tachycardic in sinus rhythm, because elevated heart rate is an independent predictor of cardiovascular morbidity and mortality. Ivabradine has been shown to reduce the composite outcome of cardiovascular death and HF hospitalisation.35 Ivabradine is PBS-subsidised for patients with a heart rate of at least 77 beats per minute in sinus rhythm on maximum tolerated doses of beta blockers.

Digoxin

Digoxin is a cardiac glycoside with positive inotropic and autonomic effects. A 2026 meta-analysis of HFrEF patients demonstrated that cardiac glycosides reduced the risk of the composite outcome of cardiovascular death and worsening HF events, primarily through a reduction in worsening HF events.36 Digoxin may be considered in patients who remain symptomatic despite optimal GDMT when the goal is to reduce the risk of hospitalisation. It should also be considered in patients with HFrEF and atrial fibrillation where additional rate control is required. Digoxin has a narrow therapeutic range and a target trough serum concentration of 0.5 to 0.9 nanograms/mL in HF. The digoxin trough concentration should be measured at steady state, 1 to 2 weeks after initiation or dose change, immediately before the next dose or at least 8 hours after the previous dose.

Hydralazine and isosorbide dinitrate

Hydralazine is an arterial vasodilator and isosorbide dinitrate is predominantly a venodilator. The combination of hydralazine and isosorbide dinitrate may be considered in patients with HFrEF who are intolerant of an ARNI, ACEi or ARB.37

 

Drugs to avoid in heart failure

Drugs that worsen HF typically promote fluid retention, increase sympathetic activity or depress myocardial contractility.38 Clinicians should always review new and concomitant drugs when initiating or up-titrating GDMT.

Drugs that promote sodium and fluid retention include nonsteroidal anti-inflammatory drugs (e.g. ibuprofen, celecoxib), corticosteroids (e.g. prednisolone), mineralocorticoids (e.g. fludrocortisone) and thiazolidinediones (e.g. pioglitazone).

Negative inotropes, such as verapamil, diltiazem, sotalol, moxonidine and the antifungal itraconazole, impair myocardial contractility and reduce cardiac output, potentially precipitating hypotension or acute decompensation.

Tricyclic antidepressants (e.g. imipramine, amitriptyline, dosulepin) can cause cardiac conduction abnormalities, including QRS widening, QT prolongation and arrhythmias. Flecainide can worsen HF through negative inotropic effects and cause potentially serious ventricular arrhythmias. Macrolide antibiotics (e.g. clarithromycin, erythromycin) and fluoroquinolones (e.g. ciprofloxacin) can prolong the QT interval and predispose to ventricular arrhythmias.

 

Conclusion

The management of HF has evolved considerably in recent years, with contemporary evidence-based therapies substantially reducing morbidity and mortality. Accurate classification according to ejection fraction, early initiation and optimisation of GDMT and the use of additional drug therapies to manage symptoms and comorbidities are key to improving outcomes. Effective care requires a multidisciplinary, patient-centred approach, with regular review to optimise treatment and minimise adverse effects.

 

Key practice points

  • ●      In patients with heart failure with reduced ejection fraction (HFrEF), initiate the 4 pillars early, namely an angiotensin receptor–neprilysin inhibitor (or angiotensin converting enzyme inhibitor or angiotensin receptor blocker), a beta blocker, a mineralocorticoid receptor antagonist (MRA) and a sodium-glucose co-transporter 2 (SGLT2) inhibitor. Start at low doses and rapidly up-titrate to maximum tolerated doses, because early optimisation reduces mortality and hospitalisation for heart failure.
  • ●      In patients with heart failure with preserved ejection fraction (HFpEF), initiate an SGLT2 inhibitor and an MRA to reduce the risk of worsening heart failure and hospitalisation.
  • ●      Use diuretics to reduce congestion and achieve euvolaemia. Once congestion has resolved, reduce the diuretic dose to the lowest effective dose to facilitate optimisation of guideline-directed medical therapy.
  • ●      Monitor patients closely, usually every 1 to 2 weeks, during treatment initiation and dose titration, including symptoms, blood pressure, heart rate, body weight, renal function, electrolytes and treatment adverse effects.
  • ●      Individualise therapy, particularly in patients with older age, frailty, multimorbidity, polypharmacy, hypotension or reduced kidney function. These factors should prompt careful treatment selection and monitoring, rather than withholding therapies with proven benefit.

This article was finalised on 30 October 2026.

Acknowledgements: The authors thank Ms Kellie Easton, Associate Professor Hitesh Patel and Ms Tory Warner for reviewing the initial draft of the manuscript.

Conflicts of interest: Ingrid Hopper has received advisory fees, speaker fees or honoraria from Boehringer Ingelheim, CSL Seqirus, Eli Lilly, Novartis, Novo Nordisk, Viatris and Healthed. Ingrid was an author on the 2018 Australian Heart Failure Guidelines and the 2023 Cardiac Society of Australia and New Zealand’s Expert Position Statement on Catheter and Surgical Ablation for Atrial Fibrillation. Ingrid is a member of the Australian Medicines Handbook board and the Therapeutic Goods Administration Advisory Committee on Medicines. Ingrid was an expert reviewer of heart failure resources for the National Prescribing Curriculum, Medicines Advice Initiative Australia, the NSW Agency for Clinical Innovation, and Veterans’ MATES.

Anna Duggan declared no conflicts of interest.

This article is peer reviewed.

 

Australian Prescriber welcomes Feedback.

 

References

  1. Atherton JJ, Sindone A, De Pasquale CG, Driscoll A, MacDonald PS, Hopper I, et al. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of heart failure 2018. Med J Aust 2018;209:363–9.
  2. Chan YK, Tuttle C, Ball J, Teng TK, Ahamed Y, Carrington MJ, et al. Current and projected burden of heart failure in the Australian adult population: a substantive but still ill-defined major health issue. BMC Health Serv Res 2016;16:501.
  3. Jones NR, Roalfe AK, Adoki I, Hobbs FDR, Taylor CJ. Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis. Eur J Heart Fail 2019;21:1306–25.
  4. Køber L, Adamo M, Ruwald AC, Tomasoni D, Anderson LJ, Andersson C, et al. 2026 ESC Guidelines for the management of heart failure. Eur Heart J 2026.
  5. Halliday BP, Wassall R, Lota AS, Khalique Z, Gregson J, Newsome S, et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet 2019;393:61–73.
  6. van Essen BJ, Ceelen DCH, Ouwerkerk W, Teng TK, Tharshana GN, Hew FM, et al. Pharmacologic Treatment of Heart Failure With Reduced Ejection Fraction: An Updated Systematic Review and Network Meta-Analysis. J Am Coll Cardiol 2025;86:2513–26.
  7. Packer M, McMurray JJV. Rapid evidence-based sequencing of foundational drugs for heart failure and a reduced ejection fraction. Eur J Heart Fail 2021;23:882–94.
  8. Sindone AP, De Pasquale C, Amerena J, Burdeniuk C, Chan A, Coats A, et al. Consensus statement on the current pharmacological prevention and management of heart failure. Med J Aust 2022;217:212–7.
  9. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993–1004.
  10. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000;355:1575–81.
  11. Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel JP. Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 1998;98:1184–91.
  12. Zhang Y, Bao YC, Wang LX, Zhao HJ, Sun J, Sun L, et al. Mineralocorticoid receptor antagonists in heart failure: a systematic review and meta-analysis. Front Cardiovasc Med 2025;12:1667236.
  13. Beavers CJ, Greene SJ. Hyperkalemia in Heart Failure with Reduced Ejection Fraction: Implications and Management. Heart Fail Rev 2025;30:1291–305.
  14. Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet 2022;400:757–67.
  15. Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet 2020;396:819–29.
  16. Meraz-Munoz AY, Weinstein J, Wald R. eGFR Decline after SGLT2 Inhibitor Initiation: The Tortoise and the Hare Reimagined. Kidney360 2021;2:1042–7.
  17. Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet 2022;400:1938–52.
  18. Wu X, Li Z, Tian Q, Ji S, Zhang C. Effectiveness of nurse-led heart failure clinic: A systematic review. Int J Nurs Sci 2024;11:315–29.
  19. Warner V, Nguyen D, Bayles T, Hopper I. Management of heart failure in older people. Journal of Pharmacy Practice and Research 2022;52:72–9.
  20. Borlaug BA, Sharma K, Shah SJ, Ho JE. Heart Failure With Preserved Ejection Fraction: JACC Scientific Statement. J Am Coll Cardiol 2023;81:1810–34.
  21. Kittleson MM, Panjrath GS, Bates K, Breathett KK, Dixon DL, Januzzi JL, Jr., et al. Management of Heart Failure With Preserved Ejection Fraction: 2026 ACC Expert Consensus Decision Pathway: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2026.
  22. Solomon SD, McMurray JJV, Vaduganathan M, Claggett B, Jhund PS, Desai AS, et al. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med 2024;391:1475–85.
  23. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014;370:1383–92.
  24. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med 2019;381:1609–20.
  25. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362:777–81.
  26. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006;27:2338–45.
  27. Nassar G, Jameson R. Diuretic Use in Heart Failure. Rev Cardiovasc Med 2025;26:39547.
  28. Chan D, Sindone AP. Iron deficiency in heart failure - more than just anaemia. Medicine Today 2025;26:61–7. https://medicinetoday.com.au/mt/2025/jan-feb/regular-series/iron-deficiency-heart-failure-more-just-anaemia
  29. Lewis GD, Malhotra R, Hernandez AF, McNulty SE, Smith A, Felker GM, et al. Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial. JAMA 2017;317:1958–66.
  30. Koskinas KC, Van Craenenbroeck EM, Antoniades C, Bluher M, Gorter TM, Hanssen H, et al. Obesity and cardiovascular disease: an ESC clinical consensus statement. Eur Heart J 2024;45:4063–98.
  31. Butler J, Shah SJ, Petrie MC, Borlaug BA, Abildstrom SZ, Davies MJ, et al. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. Lancet 2024;403:1635–48.
  32. Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med 2025;392:427–37.
  33. Bonfioli GB, Pagnesi M, Tomasoni D, Rakisheva A, Metra M. Understanding the Role of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Heart Failure. Card Fail Rev 2025;11:e19.
  34. Zannad F, O'Connor CM, Butler J, McMullan CJ, Anstrom KJ, Barash I, et al. Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials. Lancet 2025;406:1351–62.
  35. Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010;376:875–85.
  36. Damman K, van Veldhuisen DJ, Bauersachs J, Rienstra M, Mosterd A, Voors AA, et al. Efficacy and Safety of Digitalis Glycosides in Heart Failure: A Meta-Analysis. JAMA 2026;335:2029–37.
  37. Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R, Jr., Ferdinand K, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004;351:2049–57.
  38. Abdin A, Bauersachs J, Abdelhamid M, Aktaa S, Al Ghorani H, Bayes-Genis A, et al. Pharmacologic pitfalls in heart failure: A guide to drugs that may cause or exacerbate heart failure. A European Journal of Heart Failure expert consensus document. Eur J Heart Fail 2025;27:2671–90.
 

CPD for GPs questions

  • Identify and summarise three key points relevant to your scope of practice.
  • Identify the key clinical learnings that may be incorporated into the clinical assessment, work-up and/or management plan for appropriate patients.
  • If relevant, would you change any of your management strategies for those patients identified by appropriate screening, examination and investigation.

Submit answers

 

undefined

Cardiologist, Metro North Hospital and Health Service, Brisbane

undefined

Clinical Pharmacologist and Heart Failure Specialist Physician, The Alfred, Bayside Health, Melbourne

Associate Professor, School of Public Health and Preventive Medicine, Monash University, Melbourne